Every year, Malaysians are told that medical inflation is becoming unsustainable. In discussions on medical inflation in Malaysia, attention is usually directed towards the visible disputes between insurers, hospitals, doctors, and patients.
Hospitals argue that costs are rising because medicine has become more advanced and operationally expensive. Insurers argue that utilisation is excessive and financially unsustainable. Patients argue that premiums are becoming unaffordable. Doctors argue that professional autonomy is increasingly constrained.
Each perspective contains some truth. Yet these debates may obscure a more important question: what kind of health system has Malaysia gradually constructed over the past several decades?
The Malaysian system today is not merely divided administratively between public and private sectors. Increasingly, it reflects two different social understandings of illness itself.
In the public sector, illness is treated primarily as necessity. In the private sector, illness increasingly exists within the language of markets, consumption, and hierarchy.
The distinction is subtle but important.
The private patient is often no longer seen merely as a patient, but also as a customer, a policyholder, a covered life, a hospital admission, a corporate benefit recipient, or a consumer exercising purchasing power through insurance.
And systems shape behaviour.
Insurance products rarely market themselves around measurable long-term health outcomes. They are instead sold through the language of access and entitlement: larger annual limits, executive rooms, prestigious hospitals, immediate admissions, unrestricted specialist access, comprehensive benefits, and freedom from waiting.
The symbolic value of insurance increasingly lies not simply in protection from financial catastrophe, but in separation from the public experience of illness.
This distinction becomes clearer when one examines what insurance meaningfully covers and what it excludes.
A RM1 million annual limit appears reassuring in marketing materials. Yet the existence of a large financial limit alone says little about whether meaningful care is actually accessible.
Many policies in Malaysia continue to restrict or exclude conditions that carry profound public health importance and long-term human consequences, including HIV-related care, mental health conditions, chronic disease complications, rehabilitative needs, or preventive interventions.
The magnitude of theoretical coverage may therefore matter less than the substance of actual care.
One may possess a very large insurance limit while remaining poorly protected against some of the illnesses that most shape long-term wellbeing.
The issue here is not merely technical policy design. It reflects what the system chooses to value.
Health insurance increasingly finances episodes of private consumption during illness rather than the broader production of health itself. Hospitals respond rationally to this environment.
Where patients and insurers reward rapid access, technological intensity, hospitality, and specialist-driven care, hospitals naturally compete through these dimensions. Investment flows towards expansion, branding, premium infrastructure, and high-revenue service lines.
Under such conditions, it becomes difficult to separate medical value from market value.
The distinction between care that is clinically necessary and care that is commercially rewarded may gradually become blurred — not necessarily through deliberate misconduct, but through institutional normalisation.
Doctors themselves do not stand outside these pressures.
Medical ethics is often discussed as though it exists independently of economic structure. In reality, professional behaviour is deeply influenced by the systems within which medicine is practised.
In a highly stratified dual system, where private practice becomes associated with insured or affluent patients, assumptions inevitably emerge. The patient entering a private hospital may gradually become perceived not only as someone requiring care, but also as someone capable of paying for more care.
Such transitions are rarely dramatic. More often, they are incremental. More investigations become routine. More referrals become expected. More admissions become acceptable. More intervention becomes difficult to refuse.
Not always because doctors are individually unethical, but because the surrounding ecosystem continuously rewards activity, intensity, and consumer satisfaction.
The danger is not simply overt corruption. The deeper danger is moral adaptation.
Practices that may once have appeared excessive gradually become standard. Professional restraint becomes harder to sustain within systems where intervention is rewarded more consistently than conservatism.
Meanwhile, insured patients themselves adapt to the same logic.
Having paid substantial premiums, many increasingly approach health care through consumer expectations: if payment is high, utilisation must correspondingly increase.
Yet medicine does not necessarily function according to market principles.
More consumption is not always better care. More expensive care is not always higher-value care. And comfort, while deeply important to human dignity, is not synonymous with improved health outcomes.
This is perhaps the central contradiction of Malaysia’s private health care system: it increasingly sells reassurance, status, speed, and separation from public-sector discomfort, while speaking the language of health.
The result is not merely rising costs. It is the gradual commercialisation of sickness itself.
This problem extends beyond hospitals or insurance products. It also reflects a deeper national failure to organise health care around prevention, continuity, and population health.
Modern health care systems often become highly skilled at treating sick individuals while paying insufficient attention to the conditions producing unhealthy populations. Malaysia may now face a similar problem.
We continue debating which stakeholder is responsible for rising costs, while paying insufficient attention to the broader structure producing these behaviours across the entire ecosystem.
For decades, the system rewarded higher utilisation, greater intervention, broader coverage limits, larger hospitals, specialist expansion, and increasingly consumerised expectations of care.
Each stakeholder adapted rationally.
Insurers sold reassurance through ever-expanding limits. Hospitals expanded around demand for speed, prestige, and intervention. Doctors practised within systems where activity was continuously rewarded. Patients learned to equate expensive access with better care.
No single group created the problem alone. But collectively, the system may have drifted away from the original purpose of health care itself.
In this context, recent discussions around basic health insurance coverage and broader MHIT reforms may reflect a deeper recognition that health care cannot remain indefinitely organised around unlimited consumer expectations.
The political difficulty of such reforms lies partly in the fact that private health care has long been marketed not merely as protection from illness, but as separation from the constraints of the public system itself.
A sustainable health system cannot be built purely around financing increasingly expensive episodes of illness.
At some point, societies must decide whether health care exists primarily to maximise consumption during sickness, or to preserve health with dignity, equity, and restraint.
Malaysia does not need another cycle of blame between patients, doctors, hospitals, and insurers. It needs a more honest conversation about the system that has taught each of them to behave rationally in unhealthy ways.
The question is no longer only how to control medical inflation.
The deeper question is whether private health care in Malaysia is still organised around health, or increasingly around the profitable management of sickness?
The author works in Malaysia’s medical insurance sector and is currently pursuing a Master of Public Health at the University of Edinburgh. As a doctor, policyholder, health care system user, and health insurance professional, his interests include medical inflation, health systems, and the tension between health care consumption and meaningful health outcomes.
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
